OrbiMed’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,707,458
| Closed | -$38.3M | – | 121 |
|
|
2023
Q4 | $38.3M | Hold |
4,707,458
| – | – | 0.76% | 43 |
|
|
2023
Q3 | $21.4M | Hold |
4,707,458
| – | – | 0.46% | 60 |
|
|
2023
Q2 | $33.1M | Hold |
4,707,458
| – | – | 0.6% | 53 |
|
|
2023
Q1 | $28.8M | Buy |
4,707,458
+2,700,000
| +134% | +$18.6M | 0.56% | 56 |
|
|
2022
Q4 | $12.8M | Hold |
2,007,458
| – | – | 0.25% | 71 |
|
|
2022
Q3 | $19.2M | Sell |
2,007,458
-790,983
| -28% | -$9.12M | 0.36% | 66 |
|
|
2022
Q2 | $30.9M | Sell |
2,798,441
-3,834,565
| -58% | -$50.3M | 0.56% | 55 |
|
|
2022
Q1 | $110M | Buy |
6,633,006
+295,306
| +5% | +$4.57M | 1.79% | 19 |
|
|
2021
Q4 | $121M | Sell |
6,337,700
-307,400
| -5% | -$6.77M | 1.56% | 24 |
|
|
2021
Q3 | $164M | Hold |
6,645,100
| – | – | 1.8% | 13 |
|
|
2021
Q2 | $173M | Hold |
6,645,100
| – | – | 1.75% | 15 |
|
|
2021
Q1 | $210M | Hold |
6,645,100
| – | – | 1.97% | 15 |
|
|
2020
Q4 | $308M | Hold |
6,645,100
| – | – | 2.7% | 8 |
|
|
2020
Q3 | $219M | Hold |
6,645,100
| – | – | 2.75% | 7 |
|
|
2020
Q2 | $182M | Buy |
6,645,100
+1,096,774
| +20% | +$36.1M | 2.57% | 10 |
|
|
2020
Q1 | $166M | Hold |
5,548,326
| – | – | 2.79% | 9 |
|
|
2019
Q4 | $154M | Hold |
5,548,326
| – | – | 2.19% | 13 |
|
|
2019
Q3 | $101M | Hold |
5,548,326
| – | – | 1.92% | 15 |
|
|
2019
Q2 | $136M | Hold |
5,548,326
| – | – | 2.11% | 10 |
|
|
2019
Q1 | $52.8M | Hold |
5,548,326
| – | – | 0.82% | 37 |
|
|
2018
Q4 | $49.1M | Hold |
5,548,326
| – | – | 0.91% | 38 |
|
|
2018
Q3 | $62.4M | Hold |
5,548,326
| – | – | 0.75% | 40 |
|
|
2018
Q2 | $71M | Hold |
5,548,326
| – | – | 0.85% | 38 |
|
|
2018
Q1 | $93.8M | Hold |
5,548,326
| – | – | 1.16% | 29 |
|
|
2017
Q4 | $44.4M | Sell |
5,548,326
-877,300
| -14% | -$7.04M | 0.56% | 52 |
|
|
2017
Q3 | $49.8M | Buy |
6,425,626
+3,042,726
| +90% | +$19.3M | 0.48% | 63 |
|
|
2017
Q2 | $25.2M | Hold |
3,382,900
| – | – | 0.26% | 76 |
|
|
2017
Q1 | $25.2M | Hold |
3,382,900
| – | – | 0.29% | 72 |
|
|
2016
Q4 | $23.5M | Hold |
3,382,900
| – | – | 0.3% | 63 |
|
|
2016
Q3 | $27.8M | Hold |
3,382,900
| – | – | 0.32% | 67 |
|
|
2016
Q2 | $27.4M | Buy |
3,382,900
+2,360,800
| +231% | +$14.8M | 0.29% | 66 |
|
|
2016
Q1 | $5.19M | Hold |
1,022,100
| – | – | 0.05% | 114 |
|
|
2015
Q4 | $7.89M | Hold |
1,022,100
| – | – | 0.07% | 98 |
|
|
2015
Q3 | $5.89M | Hold |
1,022,100
| – | – | 0.06% | 109 |
|
|
2015
Q2 | $9.37M | Buy |
1,022,100
+22,100
| +2% | +$247K | 0.08% | 108 |
|
|
2015
Q1 | $12.1M | Buy |
+1,000,000
| New | +$11.3M | 0.1% | 95 |
|
Other funds holding IOVA
MFM
PA
ACA
OrbiMed's IOVA Position: Q1 2024 in Review
OrbiMed sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 4,707,458 shares — an estimated $38.3M sold.
OrbiMed first reported a position in IOVA in Q1 2015 and held it in 36 quarters. The position peaked at $308M in Q4 2020. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.
- OrbiMed reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
- OrbiMed sold 4,707,458 Iovance Biotherapeutics shares in Q1 2024, an estimated $38.3M.
- OrbiMed first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 36 quarters.
- OrbiMed's Iovance Biotherapeutics position peaked at $308M in Q4 2020.
- 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.
Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.